

**Study Number:** I10577

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Mouse/B6C3F1/N

**Study Number:**

**Study Gender:**

**PWG Approval Date:**

**Version:**

**PA03: Non-Neoplastic Lesion Summary with Percent Incidence**

**Test Compound:** Pyrene

**CAS Number:** 129-00-0

I10577

Female

See web page for date of PWG Approval

v1.3.7

**Date Report Requested:** 02/01/2022

**Time Report Requested:** 13:04:40

**Lab:** BRT with ILS

Study Number: I10577

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Date Report Requested: 02/01/2022

Test Type: TOX

Test Compound: Pyrene

Time Report Requested: 13:04:40

Route: Oral Gavage

CAS Number: 129-00-0

Lab: BRT with ILS

Species/Strain: Mouse/B6C3F1/N

Female: Immunopath

Treatment Groups (mg/kg)

|   | 0        | 3.1      | 6.3      | 12.5    | 25       | 50       | 100      | 200      |
|---|----------|----------|----------|---------|----------|----------|----------|----------|
| <b>Disposition Summary</b>              |          |          |          |         |          |          |          |          |
| Animals Initially In Study              | 8        | 8        | 8        | 8       | 8        | 8        | 8        | 8        |
| Censored                                |          |          |          |         |          |          |          |          |
| Early Deaths                            |          |          |          |         |          |          |          |          |
| Survivors                               |          |          |          |         |          |          |          |          |
| Scheduled Sacrifice, Terminal           | 8        | 8        | 8        | 8       | 8        | 8        | 8        | 8        |
| Number Animals Examined Microscopically | 8        | 8        | 8        | 8       | 8        | 8        | 8        | 8        |
| <b>ALIMENTARY SYSTEM</b>                |          |          |          |         |          |          |          |          |
| LIVER                                   | (8)      | (8)      | (7)      | (7)     | (8)      | (8)      | (8)      | (8)      |
| CONGESTION                              |          |          |          |         |          |          | 2 (25%)  | 1 (13%)  |
| <b>CARDIOVASCULAR SYSTEM</b>            |          |          |          |         |          |          |          |          |
| No Tissues/Organs Examined              |          |          |          |         |          |          |          |          |
| <b>ENDOCRINE SYSTEM</b>                 |          |          |          |         |          |          |          |          |
| ADRENAL GLAND                           | (8)      | (8)      | (8)      | (8)     | (8)      | (8)      | (8)      | (8)      |
| SUBCAPSULAR HYPERPLASIA                 | 8 (100%) | 8 (100%) | 8 (100%) | 7 (88%) | 8 (100%) | 8 (100%) | 8 (100%) | 8 (100%) |
| <b>GENERAL BODY SYSTEM</b>              |          |          |          |         |          |          |          |          |
| No Tissues/Organs Examined              |          |          |          |         |          |          |          |          |
| <b>GENITAL SYSTEM</b>                   |          |          |          |         |          |          |          |          |
| OVARY                                   | (6)      | (7)      | (7)      | (8)     | (7)      | (8)      | (6)      | (8)      |
| BURSA; CYST                             | 1 (17%)  |          |          |         |          |          |          |          |

Study Number: I10577

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Pyrene

CAS Number: 129-00-0

Date Report Requested: 02/01/2022

Time Report Requested: 13:04:40

Lab: BRT with ILS

Female: Immunopath

|                                    | Treatment Groups (mg/kg) |     |     |      |         |     |     |         |
|------------------------------------|--------------------------|-----|-----|------|---------|-----|-----|---------|
|                                    | 0                        | 3.1 | 6.3 | 12.5 | 25      | 50  | 100 | 200     |
| HEMATOLYMPHOID SYSTEM              |                          |     |     |      |         |     |     |         |
| BALT                               | (8)                      | (8) | (8) | (8)  | (8)     | (8) | (8) | (8)     |
| BONE MARROW                        | (8)                      | (7) | (8) | (7)  | (8)     | (8) | (8) | (8)     |
| LYMPH NODE, MESENTERIC             | (8)                      | (8) | (8) | (8)  | (8)     | (8) | (8) | (8)     |
| LYMPH NODE, POPLITEAL              | (8)                      | (7) | (7) | (7)  | (8)     | (7) | (7) | (8)     |
| SPLEEN                             | (8)                      | (7) | (8) | (8)  | (8)     | (8) | (8) | (8)     |
| THYMUS                             | (8)                      | (8) | (8) | (8)  | (8)     | (8) | (8) | (8)     |
| CYST                               |                          |     |     |      | 1 (13%) |     |     | 2 (25%) |
| INTEGUMENTARY SYSTEM               |                          |     |     |      |         |     |     |         |
| No Tissues/Organs Examined         |                          |     |     |      |         |     |     |         |
| MUSCULOSKELETAL SYSTEM             |                          |     |     |      |         |     |     |         |
| No Tissues/Organs Examined         |                          |     |     |      |         |     |     |         |
| NERVOUS SYSTEM                     |                          |     |     |      |         |     |     |         |
| No Tissues/Organs Examined         |                          |     |     |      |         |     |     |         |
| RESPIRATORY SYSTEM                 |                          |     |     |      |         |     |     |         |
| LUNG                               | (8)                      | (8) | (8) | (8)  | (8)     | (8) | (8) | (8)     |
| INFILTRATION, CELLULAR; HISTIOCYTE | 1 (13%)                  |     |     |      |         |     |     | 1 (13%) |
| SPECIAL SENSES SYSTEM              |                          |     |     |      |         |     |     |         |
| No Tissues/Organs Examined         |                          |     |     |      |         |     |     |         |
| URINARY SYSTEM                     |                          |     |     |      |         |     |     |         |
| KIDNEY                             | (8)                      | (8) | (7) | (7)  | (8)     | (8) | (8) | (8)     |

**Study Number:** I10577

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Mouse/B6C3F1/N

**PA03: Non-Neoplastic Lesion Summary with Percent Incidence**

**Test Compound:** Pyrene

**CAS Number:** 129-00-0

**Date Report Requested:** 02/01/2022

**Time Report Requested:** 13:04:40

**Lab:** BRT with ILS

LEGEND

---

Censored animals are animals not in one of the other disposition categories that are removed prior to the end of the study. The censored animals are included in the pathology data.

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

**\*\* END OF REPORT \*\***